| Bioactivity | Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS). |
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 |
| Name | Rufinamide-d2 |
| CAS | 1129491-38-8 |
| Formula | C10H6D2F2N4O |
| Molar Mass | 240.21 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [3]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. [4]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20. |
Rufinamide-d2
CAS: 1129491-38-8 F: C10H6D2F2N4O W: 240.21
Rufinamide-d2 (CGP 33101-d2) is the deuterium labeled Rufinamide. Rufinamide (E 2080) is a new antiepileptic agent that
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.